Schizophrenia is characterized by the presence of delusions and/or hallucinations, as well as disorganized speech and behavior. It is also marked by the loss of executive functions (e.g., planning, organization, concentration), emotional expression, productivity of thought and speech, and goal-directed behavior.[1] Although it is discussed here as a single entity, schizophrenia is likely composed of a group of disorders that are heterogeneous in origin despite similar symptomatology.[2] Disruptions of function involving several neurotransmitters (dopamine, glutamate, GABA, and acetylcholine) have been proposed as contributing to schizophrenia, but its etiology is likely multifactorial and remains an area of ongoing research.[3] ,[4] The neurotransmitter dopamine has received the most attention, and all medications that are approved for the treatment of schizophrenia have dopamine-blocking properties.

The disorder affects about 1% of people worldwide. It occurs across all socioeconomic groups and cultures, although patients are often socially and economically marginalized as a result of the disease and its accompanying stigma, resulting in lowered socioeconomic status. Additionally, schizophrenia appears to have a better prognosis in developing countries, where patients are more fully integrated into their communities and family units.

Risk Factors

Age. The onset of schizophrenia is typically before age 25, and the illness persists throughout life. Although the lifetime risk for men and women is similar,[5] onset is often later in women than in men, with a second peak onset around menopause, suggesting a protective role for estrogen. Peak onset for men is age 10-25, and for women it is age 25-35.

Genetic factors. Approximately half of monozygotic twins are affected when the other twin has schizophrenia.[6] Monozygotic twins reared by adoptive parents have similar rates of schizophrenia as their twin siblings raised by their biological parents, suggesting the primary importance of genetic factors. First-degree relatives of affected individuals have a ten-fold increased risk for developing schizophrenia compared with the general population. However, no specific gene has been isolated, and it is likely that multiple genes play a role.

Complications during Gestation, Delivery, and Early Life. Analgesic use during the second trimester[7] or hypertension and diuretic use during the third trimester of pregnancy may be associated with increased risk of schizophrenia for the newborn.[8] Fetal malnutrition, paternal age over 50 years,[9] and winter and spring births (presumably related to viral infections) are also associated with increased risk.

Complications during delivery (e.g., preterm labor, hemorrhage, fetal hypoxia, maternal infections) have been associated with an increased risk of developing schizophrenia later in life.[10]

Persons who were not breast-fed for at least 2 weeks have been shown to have increased prevalence of schizophrenia,[11] and a child with a genetic predisposition to schizophrenia may have a further increased risk if a childhood head injury occurs.

Maternal Toxoplasma gondii. Some interesting but inconclusive evidence indicates that maternal exposure to T gondii is a risk factor for schizophrenia in offspring.[12] ,[13] Humans can become infected with T gondii in a variety of ways, including ingestion of animal tissues and exposure to soiled cat litter. Mothers with higher T gondii immunoglobulin G (IgG) antibody levels may themselves be at a higher risk for later development of schizophrenia.[14] ,[15]

Other infections (e.g., influenza, measles) and increases in circulating inflammatory cytokines have also been suggested as potential risks factors for developing the disease.[16]

Tobacco and Cannabis Use. Limited evidence suggests an increased risk in offspring with prenatal nicotine exposure.[17] The Finnish Prenatal Study of Schizophrenia found that elevated maternal C-reactive protein (CRP) levels are significantly associated with schizophrenia in offspring.[18] An inflammatory marker, CRP levels are increased by tobacco use and poor diet. Cannabis use has been linked to the development of psychosis.[19]

Diagnosis

The history will clarify acute symptoms, and physical examination may help rule out other causes of psychosis. The diagnostic criteria of the American Psychiatric Association call for 2 or more symptoms in criterion A and the presence of B-D:[1]

  1. Delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, negative symptoms (affective flattening, reduced productivity of thought or speech, or reduced goal-directed behavior), each present for a significant portion of time during a 1-month period.
  2. Marked social or occupational dysfunction (e.g., work, self-care, and/or relationships), after the onset of symptoms.
  3. Signs of illness for at least 6 months, and at least 1 month of clear symptomatology is present.
  4. Condition not attributable to any medical condition, mental health problems, or substance abuse.

Schizophrenia cannot be diagnosed through laboratory tests or imaging studies. However, some brain-imaging studies reveal increased ventricular and decreased frontal lobe volume.[20]

Treatment

Treatment for schizophrenia is lifelong and multidisciplinary, aiming to reduce symptoms, maximize functioning, and prevent relapse. This is often challenging because affected individuals may not recognize their illness or seek treatment, or may stop treatment because of undesirable side effects, limited financial resources, or lack of access to mental health services.

A person can maintain a fairly normal lifestyle once properly treated. Emotional and physical support is an important component of treatment, and patients often have better outcomes when direct family or community support is part of their overall treatment plan.

A baseline physical and neurological examination should be performed prior to initiating medications.

Pharmacologic Therapy

Medications are the most effective treatment. Antipsychotics act as dopamine receptor antagonists, and are first-line treatments. Discontinuation of antipsychotics typically results in symptom recurrence. However, relapse is common even with continuous treatment. The disease is characterized by a waxing and waning of symptoms, necessitating close follow-up and continued support.

Typical antipsychotics (or neuroleptics), such as haloperidol or chlorpromazine, can be very effective, but they carry greater risk of tardive dyskinesia and other serious extrapyramidal adverse effects, compared with newer drugs.

Second-generation (atypical) antipsychotics, such as olanzapine, risperidone, ziprasidone, aripiprazole, and quetiapine, generally carry less risk of tardive dyskinesia, neuroleptic malignant syndrome, and other extrapyramidal symptoms. However they have a higher risk of causing metabolic syndrome, characterized by weight gain, dyslipidemia, and abnormal glucose metabolism. Aripiprazole, lurasidone, brexpiprazole, and cariprazine have lower rates of metabolic syndrome, but they carry a risk of akathisia (motor restlessness), and are not yet available in generic form. They can cost thousands of dollars per month, which currently limits their use. All antipsychotics carry a black box warning for increased risk of cerebrovascular events when given to elderly patients with dementia. Antipsychotics are associated with increased risk of all-cause mortality in older patients.

Clozapine may be used for refractory cases. It also helps treat suicidal ideation, an important consideration given that as many as 40% of persons with schizophrenia will attempt suicide.[21] Physicians need special authorization to use clozapine. Clozapine has several serious potential adverse effects, including life-threatening agranulocytosis, making weekly blood draws mandatory. Additional adverse effects include weight gain, anticholinergic effects, and increased risk of seizures.

Nonpharmacologic Therapy

Antipsychotic medication is generally considered to be an essential part of any treatment plan for schizophrenia, however the addition of non-pharmacologic interventions can substantially improve outcomes. Cognitive-behavioral therapy and family therapy are intended to help the patient and family identify warning signs of relapse and its consequences and improve treatment adherence. Family therapy has been shown to reduce relapse and re-hospitalization.[22]

Group therapy, job training, and social skills training may improve quality of life and social functioning.[23] ,[24]

Nutritional Considerations

Researchers have speculated that aspects of Western culture, including diet, may play a role in schizophrenia, citing a higher prevalence in industrialized cultures, compared with unindustrialized (especially Asian) populations. During the Industrial Revolution, intakes of saturated fat, meat, dairy products, and refined sugars paralleled an increase in schizophrenia.[25] However, these geographic differences may have been influenced by differences in reporting, and social changes have occurred simultaneously with nutritional changes. The role of nutrition, therefore, remains speculative.

The following factors have been studied for their roles in schizophrenia prevention or management:

A heart-healthy diet. Among the sequelae of schizophrenia is an increased risk of cardiovascular disease.[26] Patients’ diets are often poor, smoking and physical inactivity are common, and antipsychotic medications may contribute to weight gain, hyperglycemia, and hypertriglyceridemia.[25] ,[27] ,[28] ,[29] Metabolic syndrome is also significantly more prevalent in people with schizophrenia, even among those who have not yet started taking an antipsychotic medication.[30] A typical Western (i.e., high-fat, high-sugar) diet also reduces hippocampal expression of brain-derived neurotrophic factor (BDNF), an important growth and maintenance factor for dendrites, which is reduced in the prefrontal cortex of patients with schizophrenia. Low concentrations of BDNF have also been implicated in both coronary atherosclerosis and insulin-resistance syndrome.[31] The latter is twice as common in schizophrenia patients as it is in the general U.S. adult population and helps explain the greater incidence of coronary heart disease in these patients.[32]

A healthy body weight. Weight gain in schizophrenia patients is a concern, due to psychotropic drugs, lack of exercise, potential metabolic changes, and poor diet.[33] ,[34] A small study suggests that schizophrenic patients, especially males, may have 2-5 times more visceral fat than controls, which increases cardiovascular disease risk.[35] Evidence indicates that behavioral interventions can improve weight control in persons with schizophrenia.[29],[36] Clarification of these issues awaits further research.[37]

Adequate polyunsaturated fatty acids levels. Several studies have suggested that individuals with schizophrenia have lower serum levels of some polyunsaturated fatty acids (PUFA’s)[38] ,[39] and supplementation may slow progression in young adults.[40] However current research has failed to produce evidence for omega-3, DHA, or EPA supplementation as efficacious treatments.[41] ,[42] Schizophrenia patients likely have excess oxidative stress with increased lipid peroxidation that reduces PUFA levels[43] and oxidative stress may play a role in the psychopathology[44] and symptomatology.[45] New studies using plant compounds such as as nitric oxide,[46] polyphenols,[47] and sulforaphane[48] to reduce oxidation and improve PUFA levels suggests a potential role for antioxidants, though more research is needed.[49]

Vitamin supplementation. The B-vitamin complex, especially riboflavin, plays a key role in brain function, and supplementation in schizophrenia patients, who may be low in B-vitamins, could be beneficial. A small double-blind, placebo-controlled study found significant improvement in psychiatric symptoms with folic acid, vitamin B6, and B12 supplementation in hyperhomocysteinemic patients.[50] A similar study using folic acid and B-12 supplementation that controlled for baseline folic acid status found a similar reduction in symptoms.[51] The supplementation of the antioxidant vitamins C and E, and vitamin D when there is deficiency, may reduce symptoms.[52]

Vitamins E[53] and B6[54] are under investigation for possible effects on the progression of tardive dyskinesia.

Branched-chain amino acid supplementation. One group of investigators has found a reduction in tardive dyskinesia symptoms with the use of branched-chain amino acid formulas.[55] ,[56] ,[57] Tardive dyskinesia is associated with deficient clearance of phenylalanine, an excess of which may increase production of catecholamines and indolamines, which may drive the hyperkinetic movements of tardive dyskinesia.[40] Branched-chain amino acids compete with phenylalanine at the blood-brain barrier, reduce the entry of phenylalanine into the CNS, and subsequently reduce production of catecholamines and indolamines.

Orders

See Basic Diet Orders and Coronary Heart Disease chapters.

What to Tell the Family

Schizophrenia is a lifelong illness that requires medication and support from both mental health professionals and family members. Persons with schizophrenia are at greater than average risk for cardiovascular disease from a combination of medication, sedentary lifestyle, poor diet, and smoking. Family members can support the affected person by providing a healthful diet and a smoke-free environment, and by encouraging participation in regular physical activity. The potential benefit of additional nutritional interventions is a matter of ongoing research.

References

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. DSM-5 . 5 th ed. Arlington, VA: American Psychiatric Pub; 2013.
  2. Fischer BA, Carpenter WT: Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 34:2081, 2009  [PMID:19295511]
  3. Fischer BA, Kirkpatrick B, Carpenter WT. The neurobiology of negative symptoms and the deficit syndrome. In: Javitt DC, Kantrowitz JT, eds. The Handbook of Neurochemistry and Molecular Neurobiology: Schizophrenia . 3rd ed. New York, NY: Springer Science and Business Media LLC; 2009:507.
  4. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301, 1991  [PMID:1654746]
  5. Abel KM, Drake R, Goldstein JM: Sex differences in schizophrenia. Int Rev Psychiatry 22:417, 2010  [PMID:21047156]
  6. Kringlen E: Twin studies in schizophrenia with special emphasis on concordance figures. Am J Med Genet 97:4, 2000  [PMID:10813799]
  7. Sørensen HJ et al: Association between prenatal exposure to analgesics and risk of schizophrenia. Br J Psychiatry 185:366, 2004  [PMID:15516543]
  8. Sørensen HJ et al: Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? Am J Psychiatry 160:464, 2003  [PMID:12611826]
  9. Byrne M et al: Parental age and risk of schizophrenia: a case-control study. Arch Gen Psychiatry 60:673, 2003  [PMID:12860771]
  10. Clarke MC, Harley M, Cannon M: The role of obstetric events in schizophrenia. Schizophr Bull 32:3, 2006  [PMID:16306181]
  11. Sørensen HJ et al: Breastfeeding and risk of schizophrenia in the Copenhagen Perinatal Cohort. Acta Psychiatr Scand 112:26, 2005  [PMID:15952942]
  12. Brown AS et al: Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 162:767, 2005  [PMID:15800151]
  13. Khandaker GM et al: Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 43:239, 2013  [PMID:22717193]
  14. Pedersen MG et al: Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry 168:814, 2011  [PMID:21536690]
  15. Sutterland AL et al: Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 132:161, 2015  [PMID:25877655]
  16. Miller BJ et al: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663, 2011  [PMID:21641581]
  17. Niemelä S et al: Prenatal Nicotine Exposure and Risk of Schizophrenia Among Offspring in a National Birth Cohort. Am J Psychiatry 173:799, 2016  [PMID:27216261]
  18. Canetta S, Sourander A, Surcel H-M, et al. Elevated Maternal C-Reactive Protein is Associated with Increased Risk of Schizophrenia in a National Birth Cohort. Amer J Psychiatry . 2014;171:960-968.
  19. Kristensen K, Cadenhead KS: Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 151:151, 2007  [PMID:17383738]
  20. McCarley RW et al: MRI anatomy of schizophrenia. Biol Psychiatry 45:1099, 1999  [PMID:10331102]
  21. Meltzer HY et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82, 2003  [PMID:12511175]
  22. Bustillo J et al: The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 158:163, 2001  [PMID:11156795]
  23. Eckman TA et al: Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 149:1549, 1992  [PMID:1384364]
  24. Marder SR et al: Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 153:1585, 1996  [PMID:8942455]
  25. Peet M: Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl 47:S102, 2004  [PMID:15056602]
  26. Azad MC et al: Cardiovascular diseases among patients with schizophrenia. Asian J Psychiatr 19:28, 2016  [PMID:26957335]
  27. Faulkner G, Soundy AA, Lloyd K: Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand 108:324, 2003  [PMID:14531752]
  28. Correll CU et al: Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14:119, 2015  [PMID:26043321]
  29. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry . 2001;62 Suppl 27:15-26, discussion 40-41.
  30. Lee JS et al: Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study. Psychiatry Investig 14:44, 2017  [PMID:28096874]
  31. Chaldakov GN, Tonchev AB, Aloe L: NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines. Riv Psichiatr 44:79, 2009 Mar-Apr  [PMID:20066808]
  32. Foguet-Boreu Q et al: Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis. BMC Psychiatry 16:, 2016  [PMID:27176477]
  33. Dent R et al: Changes in body weight and psychotropic drugs: a systematic synthesis of the literature. PLoS ONE 7:, 2012  [PMID:22719834]
  34. Amani R: Is dietary pattern of schizophrenia patients different from healthy subjects? BMC Psychiatry 7:, 2007  [PMID:17474979]
  35. Konarzewska B et al: Visceral obesity in normal-weight patients suffering from chronic schizophrenia. BMC Psychiatry 14:, 2014  [PMID:24506972]
  36. O'Keefe CD et al: Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 64:907, 2003  [PMID:12927005]
  37. Oh N et al: Association Between Weight Gain and Remission Status at 3 Months in First-Episode Schizophrenia. J Clin Psychopharmacol 36:403, 2016  [PMID:27187561]
  38. Medema S et al: Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. Schizophr Bull 42:358, 2016  [PMID:26385764]
  39. Hoen WP et al: Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res 207:1, 2013  [PMID:23068078]
  40. Amminger GP et al: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146, 2010  [PMID:20124114]
  41. Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med . 2016;5:67.
  42. Pusceddu MM, Kelly P, Stanton C, Cryan JF, Dinan TG. N-3 Polyunsaturated fatty acids through the lifespan: implication for psychopathology. Int J Neuropsychopharmacol . 2016;19:pyw078-pyw101.
  43. Dietrich-Muszalska A, Kontek B: Lipid peroxidation in patients with schizophrenia. Psychiatry Clin Neurosci 64:469, 2010  [PMID:20923426]
  44. Zhang X, Chen D, Xiu M, et al. Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. J Psychiatric Res . 2013;47:1049-1053.
  45. Wu J, Kosten T, Zhang X. Free radicals, antioxidant defense systems, and schizophrenia. Progress in Neuro-Psychopharmacol Biol Psychiatry . 2013;46:200-206.
  46. Nasyrova RF et al: Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. Front Physiol 6:, 2015  [PMID:26029110]
  47. Dietrich-Muszalska A, Kopka J, Kontek B: Polyphenols from Berries of Aronia melanocarpa Reduce the Plasma Lipid Peroxidation Induced by Ziprasidone. Schizophr Res Treatment 2014:, 2014  [PMID:25061527]
  48. Shiina A et al: An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. Clin Psychopharmacol Neurosci 13:62, 2015  [PMID:25912539]
  49. Magalhães P, Dean O, Andreazza A, Berk M, Kapczinski F. Antioxidant treatments for schizophrenia. Cochrane Database of Syst Rev . 2016;5:CD008919-CD009009.
  50. Levine J et al: Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 60:265, 2006  [PMID:16412989]
  51. Roffman JL et al: Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70:481, 2013  [PMID:23467813]
  52. Brown HE, Roffman JL: Vitamin supplementation in the treatment of schizophrenia. CNS Drugs 28:611, 2014  [PMID:24846474]
  53. Pham DQ, Plakogiannis R: Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother 39:2065, 2005  [PMID:16288072]
  54. Umar MU, Isa AA, Abba AH: High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature. Ther Adv Psychopharmacol 6:152, 2016  [PMID:27141296]
  55. Richardson MA et al: Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry 160:1117, 2003  [PMID:12777270]
  56. Richardson MA et al: Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry 65:92, 2004  [PMID:14744176]
  57. Richardson MA et al: Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl) 143:358, 1999  [PMID:10367552]

Last updated: January 12, 2018

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Schizophrenia ID - 1342091 Y1 - 2018/01/12/ PB - Nutrition Guide for Clinicians UR - https://nutritionguide.pcrm.org/nutritionguide/view/Nutrition_Guide_for_Clinicians/1342091/all/Schizophrenia ER -